文献速递冠心病血脂与心血管预防

替格瑞洛与普拉格雷在糖尿病多支冠状动脉病变患者中的比较:TUXEDO-2随机临床试验

Ticagrelor vs Prasugrel in Patients With Diabetes and Multivessel Coronary Artery Disease: The TUXEDO-2 Randomized Clinical Trial.
PubMed 文献 · JAMA Cardiol · 2026-01-01

IMPORTANCE: The optimal dual antiplatelet therapy after percutaneous coronary intervention (PCI) in patients with diabetes is not clearly defined.…

要点

  • 替格瑞洛对比普拉格雷在糖尿病多支病变PCI患者中未达到非劣效性
  • 主要终点为1年死亡、非致死性心肌梗死、卒中或BARC大出血的复合终点
  • 替格瑞洛组主要终点及大出血数值上高于普拉格雷组,但差异无统计学意义

核心结论

  • 在糖尿病合并多支冠状动脉病变接受PCI的患者中,替格瑞洛在1年主要复合终点上不劣于普拉格雷的假设未获证实。

研究设计与样本

  • TUXEDO-2为研究者发起的前瞻性、开放标签、多中心、2×2析因设计、1:1随机临床试验,纳入1800例糖尿病多支病变接受PCI的患者,来自66个临床中心,入组时间2020年2月至2024年8月。

关键数值与推荐

  • 主要终点为1年死亡、非致死性心肌梗死、卒中或BARC定义的大出血的复合终点。
  • 非劣效界值预设为5%。

临床怎么用

  • 在糖尿病多支病变PCI患者中,选择P2Y12抑制剂时需权衡替格瑞洛未证实非劣效于普拉格雷的结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The optimal dual antiplatelet therapy after percutaneous coronary intervention (PCI) in patients with diabetes is not clearly defined. Although both ticagrelor and prasugrel are potent inhibitors of P2Y purinergic receptor 12 (P2Y12), evidence directly comparing their efficacy and safety in this high-risk group remains limited. OBJECTIVE: To compare the clinical outcomes of ticagrelor vs prasugrel, each in combination with aspirin, in patients with diabetes and multivessel coronary artery disease who underwent percutaneous coronary intervention. DESIGN, SETTING, AND PARTICIPANTS: The Ultrathin Strut vs Xience in a Diabetic Population With Multivessel Disease 2-India Study (TUXEDO-2) is an investigator-initiated, prospective, open-label, multicenter, 2 × 2 factorial design, 1:1 randomized clinical trial. Participants with diabetes and multivessel disease undergoing percutaneous coronary intervention were enrolled at 66 clinical sites from February 2020 to August 2024. INTERVENTIONS: Patients undergoing percutaneous coronary intervention were randomized to receive either ticagrelor or prasugrel, each in combination with low-dose aspirin. MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of death, nonfatal myocardial infarction, stroke, or major bleeding as defined by the Bleeding Academic Research Consortium at 1 year. The trial was designed to test the noninferiority of ticagrelor compared with prasugrel with a noninferiority margin of 5%. RESULTS: Among the 1800 participants randomized, mean (SD) age was 60 (10) years with 1296 (72.0%) male participants, 436 (24.2%) receiving insulin therapy, and 1530 (85.0%) with triple-vessel disease. At 1 year, the primary end point occurred in 129 participants (16.6%) taking ticagrelor and 107 participants (14.2%) taking prasugrel (P = .12). The risk difference of 2.33 percentage points (95% CI, -2.07 to 6.74 percentage points) failed to meet the prespecified threshold for noninferiority (P = .84). There was numerically higher (but not statistically significant) composite of death, myocardial infarction, stroke (10.43% vs 8.63%; P = .30), and major bleeding (8.41% vs 7.14%; P = .19) with ticagrelor when compared with prasugrel. CONCLUSIONS AND RELEVANCE: In patients with diabetes and multivessel disease undergoing PCI, ticagrelor was not noninferior to prasugrel for the reduction of primary outcome at 1 year of follow-up. TRIAL REGISTRATION: CTRI/2019/11/022088.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Bangalore S, Sinha SK, Singh R, et al. Ticagrelor vs Prasugrel in Patients With Diabetes and Multivessel Coronary Artery Disease: The TUXEDO-2 Randomized Clinical Trial. JAMA Cardiol. 2026. PMID: 41671005. doi:10.1001/jamacardio.2025.5057

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。